{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:38:46Z","timestamp":1780753126238,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202520"],"award-info":[{"award-number":["82202520"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01090-4","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T13:04:03Z","timestamp":1740229443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV"],"prefix":"10.1038","volume":"10","author":[{"given":"Shaoyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-5138","authenticated-orcid":false,"given":"Xiaoyan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-0425","authenticated-orcid":false,"given":"Yilong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengfu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4383-0760","authenticated-orcid":false,"given":"Xiaodong","family":"Zai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5456-837X","authenticated-orcid":false,"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5805-2469","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"1090_CR1","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1016\/S1473-3099(24)00229-9","volume":"11","author":"KA Moore","year":"2024","unstructured":"Moore, K. A. et al. Lassa fever research priorities: towards effective medical countermeasures by the end of the decade. Lancet Infect. Dis. 11, e696\u2013e706 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1090_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0049-5","volume":"3","author":"HJ Hallam","year":"2018","unstructured":"Hallam, H. J. et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. NPJ Vaccines. 3, 11 (2018).","journal-title":"NPJ Vaccines."},{"key":"1090_CR3","unstructured":"CEPI. Preparing for lassa vaccine trials with targeted epidemiology studies. Epidemic Preparedness Innovations (CEPI) (2020)."},{"key":"1090_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1473-3099(20)30299-1","volume":"20","author":"S Bagcchi","year":"2020","unstructured":"Bagcchi, S. Lassa fever outbreak continues across Nigeria. Lancet Infect. Dis. 20, 543 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1090_CR5","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S2666-5247(21)00178-6","volume":"3","author":"A Thielebein","year":"2022","unstructured":"Thielebein, A. et al. Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study. Lancet Microbe 3, e32\u2013e40 (2022).","journal-title":"Lancet Microbe"},{"key":"1090_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","volume":"21","author":"RF Garry","year":"2023","unstructured":"Garry, R. F. Lassa fever-the road ahead. Nat. Rev. Microbiol. 21, 87\u201396 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1090_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coviro.2019.07.003","volume":"37","author":"RW Cross","year":"2019","unstructured":"Cross, R. W. et al. Antibody therapy for Lassa fever. Curr. Opin. Virol. 37, 97\u2013104 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"1090_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14760584.2023.2290683","volume":"23","author":"H Ly","year":"2024","unstructured":"Ly, H. Progress toward the development of Lassa vaccines. Expert Rev. Vaccines. 23, 5\u20137 (2024).","journal-title":"Expert Rev. Vaccines."},{"key":"1090_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/v13030484","volume":"13","author":"M Wang","year":"2021","unstructured":"Wang, M. et al. Construction and immunological evaluation of an adenoviral vector-based vaccine candidate for lassa fever. Viruses 13, 484 (2021).","journal-title":"Viruses"},{"key":"1090_CR10","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/infdis\/jiy123","volume":"217","author":"MH Kainulainen","year":"2018","unstructured":"Kainulainen, M. H. et al. Use of a scalable replicon-particle vaccine to protect against lethal Lassa virus infection in the guinea pig model. J. Infect. Dis. 217, 1957\u20131966 (2018).","journal-title":"J. Infect. Dis."},{"key":"1090_CR11","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1016\/j.vaccine.2019.07.023","volume":"37","author":"EM Kennedy","year":"2019","unstructured":"Kennedy, E. M. et al. A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model. Vaccine 37, 5404\u20135413 (2019).","journal-title":"Vaccine"},{"key":"1090_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01012-w","volume":"9","author":"BD Carey","year":"2024","unstructured":"Carey, B. D. et al. A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs. NPJ Vaccines. 9, 220 (2024).","journal-title":"NPJ Vaccines."},{"key":"1090_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00219-x","volume":"5","author":"H M\u00fcller","year":"2020","unstructured":"M\u00fcller, H. et al. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. NPJ Vaccines. 5, 71 (2020).","journal-title":"NPJ Vaccines."},{"key":"1090_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00291-x","volume":"6","author":"RJ Fischer","year":"2021","unstructured":"Fischer, R. J. et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines. 6, 32 (2021).","journal-title":"NPJ Vaccines."},{"key":"1090_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41376-6","volume":"14","author":"AJ Ronk","year":"2023","unstructured":"Ronk, A. J. et al. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat. Commun. 14, 5603 (2023).","journal-title":"Nat. Commun."},{"key":"1090_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00930-z","volume":"9","author":"G Scher","year":"2024","unstructured":"Scher, G. et al. Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease. NPJ Vaccines. 9, 143 (2024).","journal-title":"NPJ Vaccines."},{"key":"1090_CR17","doi-asserted-by":"publisher","first-page":"eabf6348","DOI":"10.1126\/scitranslmed.abf6348","volume":"13","author":"M Mateo","year":"2021","unstructured":"Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci. Transl. Med. 13, eabf6348 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1090_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37050-6","volume":"14","author":"M Mateo","year":"2023","unstructured":"Mateo, M. et al. Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys. Nat. Commun. 14, 1352 (2023).","journal-title":"Nat. Commun."},{"key":"1090_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/vaccines1030262","volume":"1","author":"KA Cashman","year":"2013","unstructured":"Cashman, K. A. et al. Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a guinea pig disease model when delivered by dermal electroporation. Vaccines 1, 262\u2013277 (2013).","journal-title":"Vaccines"},{"key":"1090_CR20","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1080\/21645515.2019.1616499","volume":"15","author":"J Jiang","year":"2019","unstructured":"Jiang, J. et al. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques. Hum. Vaccines Immunother. 15, 2066\u20132074 (2019).","journal-title":"Hum. Vaccines Immunother."},{"key":"1090_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0104-x","volume":"4","author":"DR Stein","year":"2019","unstructured":"Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines. 4, 8 (2019).","journal-title":"NPJ Vaccines."},{"key":"1090_CR22","doi-asserted-by":"crossref","unstructured":"Cross, R. W. et al. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus. Cell Rep Med. 5, (2022).","DOI":"10.1016\/j.xcrm.2024.101392"},{"key":"1090_CR23","doi-asserted-by":"publisher","first-page":"e2304876120","DOI":"10.1073\/pnas.2304876120","volume":"120","author":"RW Cross","year":"2023","unstructured":"Cross, R. W. et al. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proc. Natl Acad. Sci. 120, e2304876120 (2023).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1090_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01278-22","volume":"13","author":"TK Buck","year":"2022","unstructured":"Buck, T. K. et al. Neutralizing Antibodies against Lassa Virus Lineage I. mBio 13, e01278-22 (2022).","journal-title":"mBio"},{"key":"1090_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00189-18","volume":"3","author":"F Amanat","year":"2018","unstructured":"Amanat, F. et al. Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses. mSphere 3, e00189-18 (2018).","journal-title":"mSphere"},{"key":"1090_CR26","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.chom.2022.10.018","volume":"30","author":"PJM Brouwer","year":"2022","unstructured":"Brouwer, P. J. M. et al. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection. Cell Host Microbe 30, 1759\u20131772 (2022).","journal-title":"Cell Host Microbe"},{"key":"1090_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-04429-2","volume":"603","author":"M Katz","year":"2022","unstructured":"Katz, M. et al. Structure and receptor recognition by the Lassa virus spike complex. Nature 603, 174\u2013179 (2022).","journal-title":"Nature"},{"key":"1090_CR28","doi-asserted-by":"publisher","first-page":"112524","DOI":"10.1016\/j.celrep.2023.112524","volume":"42","author":"HR Perrett","year":"2023","unstructured":"Perrett, H. R. et al. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies. Cell Rep. 42, 112524 (2023).","journal-title":"Cell Rep."},{"key":"1090_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).","journal-title":"Nat. Commun."},{"key":"1090_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1126\/science.aam7260","volume":"356","author":"KM Hastie","year":"2017","unstructured":"Hastie, K. M. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923\u2013928 (2017).","journal-title":"Science"},{"key":"1090_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.chom.2021.02.002","volume":"29","author":"RW Sanders","year":"2021","unstructured":"Sanders, R. W. & Moore, J. P. Virus vaccines: proteins prefer prolines. Cell Host Microbe 29, 327\u2013333 (2021).","journal-title":"Cell Host Microbe"},{"key":"1090_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coi.2020.03.013","volume":"65","author":"AB Ward","year":"2020","unstructured":"Ward, A. B. & Wilson, I. A. Innovations in structure-based antigen design and immune monitoring for next generation vaccines. Curr. Opin. Immunol. 65, 50\u201356 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"1090_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau6769","volume":"4","author":"L He","year":"2018","unstructured":"He, L. et al. HIV-1 vaccine design through minimizing envelope metastability. Sci. Adv. 4, e6769 (2018).","journal-title":"Sci. Adv."},{"key":"1090_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113\u20131117 (2013).","journal-title":"Science"},{"key":"1090_CR35","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"1090_CR36","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382 (2020).","journal-title":"Cell"},{"key":"1090_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44534-y","volume":"15","author":"J Gorman","year":"2024","unstructured":"Gorman, J. et al. Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nat. Commun. 15, 285 (2024).","journal-title":"Nat. Commun."},{"key":"1090_CR38","doi-asserted-by":"publisher","first-page":"110841","DOI":"10.1016\/j.celrep.2022.110841","volume":"39","author":"AS Enriquez","year":"2022","unstructured":"Enriquez, A. S. et al. Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. Cell Rep. 39, 110841 (2022).","journal-title":"Cell Rep."},{"key":"1090_CR39","doi-asserted-by":"publisher","first-page":"114708","DOI":"10.1016\/j.celrep.2024.114708","volume":"43","author":"PJM Brouwer","year":"2024","unstructured":"Brouwer, P. J. M. et al. Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses. Cell Rep. 43, 114708 (2024).","journal-title":"Cell Rep."},{"key":"1090_CR40","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","volume":"178","author":"KM Hastie","year":"2019","unstructured":"Hastie, K. M. et al. Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization. Cell 178, 1004\u20131015 (2019).","journal-title":"Cell"},{"key":"1090_CR41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.virs.2024.06.001","volume":"39","author":"J Guo","year":"2024","unstructured":"Guo, J. et al. Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch. Virol. Sin. 39, 600\u2013608 (2024).","journal-title":"Virol. Sin."},{"key":"1090_CR42","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1073\/pnas.1803990115","volume":"115","author":"Y Watanabe","year":"2018","unstructured":"Watanabe, Y. et al. Structure of the Lassa virus glycan shield provides a model for immunological resistance. Proc. Natl. Acad. Sci. USA 115, 7320\u20137325 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1090_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09200-8","volume":"24","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Spatio-temporal spread and evolution of Lassa virus in West Africa. BMC Infect. Dis. 24, 314 (2024).","journal-title":"BMC Infect. Dis."},{"key":"1090_CR44","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1126\/science.282.5396.2079","volume":"282","author":"W Cao","year":"1998","unstructured":"Cao, W. Identification of \u03b1-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282, 2079\u20132081 (1998).","journal-title":"Science"},{"key":"1090_CR45","doi-asserted-by":"crossref","unstructured":"Wan, L. et al. Structure and assembly of the dystrophin glycoprotein complex. Nature (2024).","DOI":"10.1038\/s41586-024-08310-2"},{"key":"1090_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01443-19","volume":"93","author":"S Zhu","year":"2019","unstructured":"Zhu, S. et al. Comprehensive interactome analysis reveals that STT3B is required for N-glycosylation of lassa virus glycoprotein. J. Virol. 93, e01443-19 (2019).","journal-title":"J. Virol."},{"key":"1090_CR47","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1016\/j.vaccine.2017.07.101","volume":"35","author":"Q Li","year":"2017","unstructured":"Li, Q. et al. An LASV GPC pseudotyped virus-based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. Vaccine 35, 5172\u20135178 (2017).","journal-title":"Vaccine"},{"key":"1090_CR48","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.immuni.2023.06.019","volume":"56","author":"JM Kastenschmidt","year":"2023","unstructured":"Kastenschmidt, J. M. et al. Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. Immunity 56, 1910\u20131926 (2023).","journal-title":"Immunity"},{"key":"1090_CR49","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1016\/j.immuni.2023.10.009","volume":"56","author":"M Zehner","year":"2023","unstructured":"Zehner, M. et al. Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer. Immunity 56, 2602\u20132620 (2023).","journal-title":"Immunity"},{"key":"1090_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"1090_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53616-4","volume":"15","author":"C Hoffmann","year":"2024","unstructured":"Hoffmann, C. et al. Lassa virus persistence with high viral titers following experimental infection in its natural reservoir host, Mastomys natalensis. Nat. Commun. 15, 9319 (2024).","journal-title":"Nat. Commun."},{"key":"1090_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2356149","volume":"13","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. A novel BSL-2 Lassa virus reverse genetics system modeling the complete viral life cycle. Emerg. Microbes Infect. 13, 2356149 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1090_CR53","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.immuni.2024.06.013","volume":"57","author":"CR Carr","year":"2024","unstructured":"Carr, C. R. et al. Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex. Immunity 57, 2061\u20132076 (2024).","journal-title":"Immunity"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01090-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T13:04:06Z","timestamp":1740229446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01090-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01090-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}